Registered Rwanda · Rwanda FDA

NIFLURIL CAPSULE

Niflumic acid 250 mg

Rwanda FDA-HMP-MA-0546 Capsules 250 mg

What it does

Niflumic acid is a medication used to relieve pain and reduce inflammation.

Commonly used for: pain relief (analgesia), inflammation reduction (anti-inflammatory)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-0546
Registration date
05/10/2023
Expiry date
04/10/2028
Status
Registered
Active ingredient
Niflumic acid 250 mg
Dosage form
Capsules
Strength
250 mg
Pack size
30 capsules
Therapeutic class
-
Manufacturer / MAH
Upsa
Applicant / LTR
UPSA, FRANCE
Country of origin
FRANCE
Manufacturer location
979 Av. des Pyrénées, 47520 Le Passage, France

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:29 · updated 2026-09-21 02:30:20

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Niflumic acid is a medication used to relieve pain and reduce inflammation.

What it treats

  • pain relief (analgesia)
  • inflammation reduction (anti-inflammatory)

How it works

It works by blocking certain substances in the body that cause pain and swelling.

Who it's for

It is suitable for adults and children who need relief from pain and inflammation.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: niflumic

Niflumic acid is a non-steroidal anti-inflammatory drug (NSAID) belonging to the fenamate class. It is primarily used in the management of pain and inflammation associated with various conditions, including musculoskeletal disorders and dysmenorrhea. Niflumic acid works by inhibiting the production of prostaglandins, which are mediators of inflammation and pain.

Indications

  • Pain relief in musculoskeletal disorders
  • Management of dysmenorrhea
  • Treatment of rheumatoid arthritis
  • Management of osteoarthritis

Dosage

Children: Refer to the BNF for Children for appropriate dosing information, as it is important to tailor the dosage to the child's age, weight, and specific condition.

Adults: Refer to the specific BNF guidelines for dosing information, as dosage may vary based on the condition being treated and individual patient characteristics.

Mechanism of action

Niflumic acid exerts its anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, leading to a decrease in the synthesis of prostaglandins. This reduction in prostaglandin levels results in decreased inflammation, pain, and fever.

Pharmacodynamics

The pharmacodynamic effects of niflumic acid include analgesia, anti-inflammatory action, and antipyresis. It is effective in alleviating pain and reducing inflammation by modulating the arachidonic acid pathway, thus reducing the effects of inflammatory mediators.

Pharmacokinetics

Niflumic acid is rapidly absorbed following oral administration, with peak plasma concentrations typically occurring within 1 to 2 hours. It is highly protein-bound, primarily to albumin. The drug undergoes hepatic metabolism and is eliminated mainly through the urine. The half-life of niflumic acid ranges from 1.5 to 3 hours, but this can vary based on individual patient factors.

Contra-indications

  • Hypersensitivity to niflumic acid or any of its components
  • Active gastrointestinal bleeding or ulceration
  • Severe heart failure
  • Renal impairment
  • Pregnancy (third trimester)

Adverse effects

  • Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain)
  • Headache
  • Dizziness
  • Rash or other hypersensitivity reactions
  • Increased liver enzymes
  • Renal toxicity
  • Cardiovascular effects (hypertension, edema)

Interactions

  • Increased risk of gastrointestinal toxicity with other NSAIDs or corticosteroids
  • Potential interaction with anticoagulants, increasing the risk of bleeding
  • Diuretics may have reduced effectiveness
  • Lithium levels may be increased

Precautions

  • Use with caution in patients with a history of peptic ulcer disease
  • Monitor renal function in patients with pre-existing kidney disease
  • Caution in patients with cardiovascular disease
  • Not recommended for use in children without medical advice

Pregnancy

Niflumic acid is not recommended during pregnancy, particularly in the third trimester due to potential effects on fetal cardiovascular function.

Breast-feeding

Use with caution; effects on nursing infants are unknown.

Storage

Store at room temperature, away from moisture and light.

Formulations

  • Oral tablets
  • Oral suspension
  • Topical gel

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.